The inorganic NItrate and eXercise performance in Heart Failure (iNIX-HF) phase II clinical trial: Rationale and study design

Background

Heart failure (HF) is a debilitating and often fatal disease that affects millions of people worldwide. Diminished nitric oxide synthesis, signaling, and bioavailability are believed to contribute to poor skeletal muscle function and aerobic capacity. The aim of this clinical trial (iNIX-HF) is to determine the acute and longer-term effectiveness of inorganic nitrate supplementation on exercise performance in patients with HF with reduced ejection fraction (HFrEF).

Methods

This clinical trial is a double-blind, placebo-controlled, randomized, parallel-arm design study in which patients with HFrEF (n = 75) are randomized to receive 10 mmol potassium nitrate (KNO3) or a placebo capsule daily for 6 wk. Primary outcome measures are muscle power determined by isokinetic dynamometry and peak aerobic capacity (VO2peak) determined during an incremental treadmill exercise test. Endpoints include the acute effects of a single dose of KNO3 and longer-term effects of 6 wk of KNO3. The study is adequately powered to detect expected increases in these outcomes at P < 0.05 with 1-β>0.80.

Discussion

The iNIX-HF phase II clinical trial will evaluate the effectiveness of inorganic nitrate supplements as a new treatment to ameliorate poor exercise capacity in HFrEF. This study also will provide critical preliminary data for a future 'pivotal', phase III, multi-center trial of the effectiveness of nitrate supplements not only for improving exercise performance, but also for improving symptoms and decreasing other major cardiovascular endpoints. The potential public health impact of identifying a new, relatively inexpensive, safe, and effective treatment that improves overall exercise performance in patients with HFrEF is significant.

Does continuous heparinization influence platelet function in the intensive care patient?

OBJECTIVE

To study the influence of continuous administration of heparin on platelet function in intensive care patients.

DESIGN

Prospective, serial investigation.

SETTING

Clinical investigation on a surgical and neurosurgical intensive care unit in a university hospital.

PATIENTS

The study included 45 patients: 15 postoperative with patients sepsis (Acute Physiology and Chronic Health Evaluation II score between 15 and 25), 15 trauma patients (Injury Severity Score 15 to 25), and 15 neurosurgical patients.

INTERVENTIONS

Management of the patients was carried out according to the guidelines for modern intensive care therapy. Sepsis and trauma patients received standard (unfractionated) heparin continuously [aim: an activated partial thromboplastin time (aPTT) approximately 2.0 times normal value; sepsis-heparin and trauma-heparin patients], whereas neurosurgical patients received no heparin (neurosurgical patients).

MEASUREMENTS AND RESULTS

From arterial blood samples, platelet aggregation was measured by the turbidimetric method. Platelet aggregation was induced by adenosine diphosphate (ADP; 2.0 mumol/l), collagen (10 micrograms/ml), and epinephrine (25 mumol/l). Measurements were carried out on the day of diagnosis of sepsis or 12 h after hemodynamic stabilization (trauma and neurosurgery patients) (baseline) and during the next 5 days at 12.00 noon. Standard coagulation parameters [platelet count and fibrinogen and antithrombin III (AT III) plasma concentrations] were also monitored. Heparin 4-10 U/kg per h (mean dose: approximately 500 U/h) was necessary to reach an aPTT of about 2.0 times normal. Platelet count was highest in the neurosurgical patients, but it did not decrease after heparin administration to the trauma and sepsis patients. AT III and fibrinogen plasma levels were similar in the three groups of patients. In the sepsis group, platelet aggregation variables decreased significantly (e.g., epinephrine-induced maximum platelet aggregation:-45 relative % from baseline value). Platelet function recovered during the study and even exceeded baseline values (e.g., ADP-induced maximum platelet aggregation: +42.5 relative % from baseline value). Continuous heparinization did not blunt this increase of platelet aggregation variables. In the heparinized trauma patients, platelet aggregation variables remained almost stable and were no different to platelet aggregation data in the untreated neurosurgical patients.

CONCLUSIONS

Continuous administration of heparin with an average dose of approximately 500 U/h did not negatively influence platelet function in the trauma patients. Recovery from reduced platelet function in the sepsis group was not affected by continuous heparinization. Thus, continuous heparinization with this dose appears to be safe with regard to platelet function in the intensive care patient.

Variability in the quantitation of mitral regurgitation by Doppler color flow mapping: comparison of transthoracic and transesophageal studies

OBJECTIVES

This study was designed to assess the most accurate and reproducible methods to quantitate mitral regurgitation by color flow transthoracic and transesophageal echocardiography.

BACKGROUND

Quantitative measurements of mitral regurgitant jets have resulted in an intraobserver and interobserver variability of up to 20%. Few data are available evaluating the various techniques by which mitral regurgitant jets are quantitated.

METHODS

Forty patients who underwent cardiac catheterization and both transesophageal and transthoracic echocardiography within 1 week were studied. Two boundaries of the color regurgitant jet area were identified and quantitated: 1) the central aliased core of the regurgitant jet with the mosaic pattern excluding any swirling low velocity flow; and 2) the largest definable area of the regurgitant flow, including low velocity flow considered to be part of the regurgitant jet.

RESULTS

The total regurgitant areas obtained by transthoracic and transesophageal studies did not differ (5.7 +/- 4.6 vs. 5.7 +/- 3.7 cm2; p = NS). However, the transesophageal mosaics were significantly larger than those obtained by transthoracic echocardiography (3.6 +/- 3.1 vs. 2.8 +/- 3.4 cm2; p less than 0.01). In transthoracic studies observer variability was higher when the mosaic aspect of the regurgitant jet rather than the total regurgitant area was measured (24 +/- 20 vs. 16 +/- 11%; p less than 0.05). In contrast, in transesophageal studies variability was lower when the mosaic area rather than the total regurgitant area was measured (11 +/- 12% vs. 18 +/- 18%; p less than 0.05). The best correlations with left ventriculography were obtained by using the absolute total regurgitant area (r = 0.72) for transthoracic studies and the mosaic area of the jets (r = 0.87) for transesophageal studies.

CONCLUSIONS

Doppler color flow jet areas correlate closely with angiographic results in the evaluation of mitral regurgitation. The total regurgitant area (including the surrounding swirling flow) in transthoracic studies and the aliased core of the regurgitant jet (mosaic) in transesophageal studies appear to be the most accurate and reproducible measurements for evaluating mitral regurgitation.

Quantitation of mitral regurgitation by transesophageal echocardiography with Doppler color flow mapping: correlation with cardiac catheterization

Eighty consecutive patients who underwent both left ventriculography and single-plane transesophageal echocardiography with Doppler color flow mapping were studied to compare the two techniques in the assessment of mitral regurgitation. Only the mosaic aspect of the regurgitant jet was included in the measurements. Values for inter- and intraobserver variability for the maximal regurgitant area measurements were 10 +/- 9% and 9 +/- 8%, respectively. The best correlation between angiography and Doppler color flow imaging was obtained with the maximal regurgitant area (r = 0.90). A maximal regurgitant area less than 3 cm2 predicted mild mitral regurgitation with a sensitivity of 96%, specificity of 100% and a predictive accuracy of 98%, whereas a maximal regurgitant area greater than 6 cm2 predicted severe mitral regurgitation with a sensitivity of 91%, a specificity of 100% and a predictive accuracy of 98%. A strong, although inferior, correlation was found for the maximal regurgitant area/left atrial area ratio (r = 0.81). A ratio less than 20% predicted mild mitral regurgitation with 94% accuracy, whereas a ratio greater than 35% predicted severe mitral regurgitation with 85% accuracy. Thus, single-plane transesophageal echocardiography with Doppler color flow mapping is an exquisitely sensitive technique for the diagnosis of mitral regurgitation. Minimal degrees of mitral regurgitation can be detected in approximately 62% of patients in whom no mitral regurgitation is detected by angiography. The mosaic maximal regurgitant area is a simple and easily obtainable Doppler echocardiographic index that provides an accurate estimation of mitral regurgitation severity.

Comparison of transthoracic and transesophageal echocardiography for assessment of left-sided valvular regurgitation

To compare transthoracic and transesophageal echocardiography in the clinical assessment of left-sided valvular regurgitation, 118 patients who underwent both transesophageal and transthoracic echocardiographic studies within a 24-hour period were included in this study. Presence or absence of aortic regurgitation was identified concordantly by both techniques in 93 patients (79%). Complete agreement between both techniques was found in 88 patients (75%). Presence or absence of mitral regurgitation was identified concordantly by both techniques in 89 patients (75%). Complete agreement in grade was found in only 74 patients (63%). Twenty-nine patients (25%) had mitral regurgitation detected by transesophageal echocardiography, but not by transthoracic echocardiography. Four of these patients (14%) had significant (2 to 3+) mitral regurgitation. Differences between transesophageal and transthoracic echocardiography do not appear to be clinically important in patients with aortic regurgitation. In mitral regurgitation, significant differences exist between these 2 techniques, with transesophageal echocardiography being much more sensitive.

Evaluation of pulmonary venous flow by transesophageal echocardiography in subjects with a normal heart: comparison with transthoracic echocardiography

Nineteen normal subjects and five patients with atrial fibrillation underwent transesophageal and transthoracic echocardiographic studies to evaluate the normal pulmonary venous flow pattern, compare right and left pulmonary venous flow and assess the effect of sample volume location on pulmonary venous flow velocities. Best quality tracings were obtained by transesophageal echocardiography. Anterograde flow during systole and diastole was observed in all patients by both techniques. Reversed flow during atrial contraction was observed with transesophageal echocardiography in 18 of the 19 subjects in normal sinus rhythm, but in only 7 subjects with transthoracic echocardiography. Two forward peaks during ventricular systole were clearly identified in 14 subjects (73%) with transesophageal echocardiography, but in none with the transthoracic technique. The early systolic wave immediately followed the reversed flow during atrial contraction and was strongly related to the timing of atrial contraction (r = 0.78; p less than 0.001), but not to the timing of ventricular contraction, and appeared to be secondary to atrial relaxation. Conversely, the late systolic wave was temporally related to ventricular ejection (r = 0.66; p less than 0.001), peaking 100 ms before the end of the aortic valve closure and was unrelated to atrial contraction time. Quantitatively, significantly higher peak systolic flow velocities were obtained in the left upper pulmonary vein compared with the right upper pulmonary vein (60 +/- 17 vs. 52 +/- 15 cm/s; p less than 0.05) and by transesophageal echocardiography compared with transthoracic studies (60 +/- 17 vs. 50 +/- 14 cm/s; p less than 0.05). Increasing depth of interrogation beyond 1 cm from the vein orifice resulted in a significant decrease in the number of interpretable tracings.(ABSTRACT TRUNCATED AT 250 WORDS)

Effect of mitral regurgitation on pulmonary venous velocities derived from transesophageal echocardiography color-guided pulsed Doppler imaging

The effect of mitral regurgitation on pulmonary venous flow velocity was studied in 66 patients undergoing transesophageal echocardiography. Nine patients were studied intraoperatively before and after surgery, so that 75 pulmonary venous flow tracings were analyzed. Fifty-four patients had no significant (0 to 1+) mitral regurgitation and 21 had significant (2 to 3+) mitral regurgitation. Comparison of both groups revealed significant differences in the pulmonary venous flow pattern. In patients with no significant mitral regurgitation, the peak systolic velocity was higher (55 +/- 16 vs. -4 +/- 16 cm/s; p less than 0.0001) and the peak diastolic velocity was lower (43 +/- 13 vs. 59 +/- 17 cm/s; p less than 0.01) when compared with values in patients with significant mitral regurgitation. Consequently, the peak systolic/diastolic velocity ratio was significantly higher in the patients without significant mitral regurgitation (1.4 +/- 0.5 vs. 0.4 +/- 1.3; p less than 0.0001). The same trend was noted with respect to the systolic and diastolic velocity integrals. As the degree of mitral regurgitation increased, the peak diastolic velocity and diastolic velocity integral increased, whereas the peak systolic velocity and systolic velocity integral decreased. In patients with severe mitral regurgitation, the systolic flow became reversed (retrograde). The sensitivity of reversed systolic flow for severe mitral regurgitation was 90% (9 of 10), the specificity was 100% (65 of 65), the positive predictive value was 100% (9 of 9), the negative predictive value was 98% (65 of 66) and the predictive accuracy was 99% (74 of 75).(ABSTRACT TRUNCATED AT 250 WORDS)